Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
|
|
文献详情
编号/登记号：
注册时间：
研究开始时间：
研究结束时间：
项目类型：
本院角色：
多中心研究：
招募状态：
试验分期：
研究疾病/适应症：
研究类型：
研究单位：[1]Pfizer[2]The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China, 230022[3]Second Affiliated hospital of Anhui Medical University Hefei, Anhui, China, 230601[4]The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing, China, 400016[5]The First hospital of LanZhou university Lanzhou, Gansu, China, 730000[6]Breast Surgery of The Second Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China, 510260[7]SUN YAT-SEN Memorial Hospital , SUN YAT-SEN University Guangzhou, Guangdong, China, 510260[8]Cancer Hospital of Shantou University Medical College Shantou, Guangdong, China, 515041[9]Thyroid and breast surgery Shenzhen City, Guangdong, China, 518035[10]Affiliated hospital of Guangdong medical college ZhanJiang, Guangdong, China, 524001[11]Hainan General Hospital Haikou, Hainan, China, 570311[12]Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050011河北医科大学第四医院[13]Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China, 150081[14]The First Affiliated Hospital of Xinxiang Medical University Weihui, Henan, China, 453100[15]Henan Cancer Hospital Zhengzhou, Henan, China, 450000[16]Henan provincial people's hospital Zhengzhou, Henan, China, 450000[17]The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China, 450000[18]Jingzhou Hospital Tongji Medical College Huazhong university of science and Technology Jingzhou, Hubei, China, 434020[19]Breast and thyroid surgery of the Central Hospital of WuHan WuHan, Hubei, China, 430014[20]Hunan Provincial People's Hospital Changsha, Hunan, China, 410005[21]Xiangya Hospital Central South University /Department of Breast Changsha, Hunan, China, 410008[22]The Affiliated Hospital of inner Mongolia medical university Hu He Hao Te, Inner Mongolia, China, 010021[23]Changzhou No.2 People's Hospital Changzhou, Jiangsu, China, 213004[24]Jiangsu Cancer Hospital/ Surgery Department Nanjing, Jiangsu, China, 210000[25]Jinling Hospital Nanjing, Jiangsu, China, 210002[26]Jiangsu Province Hospital/ Surgery Department Nanjing, Jiangsu, China, 210029[27]Nanjing Maternity and Child Health Care Hospital/Department of Breast Surgery Nanjing, Jiangsu, China[28]Suzhou Municipal Hospital Suzhou, Jiangsu, China, 215002[29]The first hospital of jilin university Changchun, Jilin, China, 130021[30]The Fourth Affiliated Hospital Of China Medical University ShenYang, Liaoning, China, 110032[31]The First Affiliated Hospital of The Fourth Military Medical University Xi'an, Shaanxi, China, 710032[32]The First Affiliated Hospital of Xi'an Jiaotong University Xi'an, Shaanxi, China, 710061[33]Linyi People's Hospital Linyi, Shandong, China, 276000[34]The Affiliated Hospital of Qingdao University Qingdao, Shandong, China, 266061[35]Qingdao municipal Hospital Qingdao, Shandong, China, 266072[36]Breast Surgery of The Weifang People's Hospital Weifang, Shandong, China, 261041[37]Breast Surgery of YanTai Yu Huang Ding Hospital Yan Tai, Shandong, China, 264000[38]Breast and thyroid surgery of Central Hospital of Zibo Zibo, Shandong, China, 255036[39]West China Hospital, Sichuan University/ Oncology Department Chengdu, Sichuan, China, 610041[40]Sichuan Provincial People's Hospital Chengdu, Sichuan, China, 610072[41]Affiliated Hospital of North Sichuan Medical College Nanchong, Sichuan, China, 637000[42]Tianjin Cancer Hospital/Breast cancer department Tianjin, Tianjin, China, 300060[43]Affiliated Cancer Hospital of Xinjiang Medical University Urumchi, Xinjiang, China, 830000[44]Yunnan Cancer Hospital Kunming, Yunnan, China, 650118[45]Zhejiang Cancer Hospital Hangzhou, Zhejiang, China, 310022[46]Cancer Hospital Chinese Academy of medical sciences Beijing, China, 100021[47]Fifth Medical Center of the PLA General Hospital Beijing, China, 100071[48]Beijing Cancer Hospital Beijing, China, 100142[49]Peking University Third Hospital/Department of Oncology Beijing, China, 100191[50]China-Japan Friendship Hospital Beijing, China[51]Fudan University Shanghai Cancer center/Department of Breast Surgery Shanghai, China, 200032[52]Yangpu District Central Hospital Shanghai, China, 200090[53]Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine Shanghai, China, 200092[54]The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department Bengbu, Anhui, China, 233004
Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years of tamoxifen & are switched to Aromasin® for completion of a total of 5 consecutive years of adjuvant hormonal therapy by State Food and Drug Administration (SFDA) with clinical trial waive. While Aromasin® has been used in China for adjuvant therapy of breast cancer since then, there is currently lack of systematic collection and analysis for the efficacy and safety data of Aromasin® adjuvant setting in Chinese population. The Aromasin® Interventional Study is being proposed to collect data systematically and to assess the efficacy and safety of Aromasin® adjuvant setting in Chinese population.
